Navigation Links
NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal treatments based on the NexACT(R) drug delivery technology, today announced that Novartis Pharma AG has completed patient enrollment for Phase III clinical trials for NM100060, a topical treatment for onychomycosis (nail fungus). Pursuant to the terms of the licensing agreement with Novartis, NexMed will be entitled to a milestone payment early next year. NexMed entered into an exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM10060.

NM100060 is a topical application of Lamisil(R) (terbinafine), formulated with terbinafine and the Company's patented NexACT permeation enhancer, which facilitates the delivery of the drug into the nail bed, where the fungus resides.

About NexMed

NexMed, Inc. is an emerging drug developer that is leveraging its proprietary drug technology to develop a significant pipeline of innovative pharmaceutical products to address significant unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT(R) into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity. For further information about the Company, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to maintain reduced expenditures, enter into partnering agreements, pursue growth opportunities, and/or
'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, announced today that it has ... shares of common stock and 3,605,042 unregistered warrants ... price for one registered share of common stock ... share of common stock will be $3.475.  The ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... 2 Medical Services,International Inc. (Pink Sheets: MSITF) is ... Fever Kit is increasing. Dengue Fever is,spreading across Latin ... in decades causing agonizing joint pain for hundreds of ... year. This year so far 630,356 cases have ...
... spans paleogenomics, paired-end mapping, and ... gene expression ... a Roche,company, is the subject of three ground-breaking studies published ... Sequencer(TM),system. The studies, entitled "Paired-End Mapping Reveals Extensive Genomic,Structural Variation ...
Cached Medicine Technology:Demand for VScan Dengue Fever Test Kits Increases 2Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 2Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 3Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 4
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... News) -- The U.S. Food and Drug Administration approved a ... part of a class of once-a-week injectable drugs that help ... "Trulicity is a new treatment option, which can ... control blood sugar levels in the overall management of type ... Office of Drug Evaluation II, said in an agency news ...
(Date:9/19/2014)... 2014 The Alliance for Bangladesh ... the National Fire Protection Association (NFPA), a recognized ... today in a Memorandum of Understanding signed by ... and other stakeholders with information, guidance and access ... health and safety of workers in ready-made garment ...
Breaking Medicine News(10 mins):Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... of Nursing faculty member Rachel Jones has been selected ... for Community Engagement in Research. This award is for ... in part on data from Newark or Northern New ... Provosts Awards for Community Engagement to acknowledge the valuable ...
... For the first time, researchers have,identified structural ... The results of the study, conducted by ... in Charlottesville and The Children,s Hospital,of Philadelphia in ... the Radiological Society of North America (RSNA)., ...
... Can Learn activities help students identify their unique qualities ... while appreciating those ... All Kids Can, in,partnership with Scholastic, announced today the distribution ... inspire students,to discover their own special abilities and qualities and ...
... University of Pennsylvania School of Medicine and other study ... a non-invasive technique that excites neurons in the brain ... a safe and effective, non-drug treatment with minimal side ... other treatment options without benefit. , This ...
... Women who live in urban areas have denser breasts, ... to a study presented today at the annual meeting ... living in cities need to pay more attention to ... F.R.C.S., F.R.C.R., director of The London Breast Institute at ...
... New Haven, Conn. Bioengineers at Yale and Cornell ... and remains at the site of brain tumors ... according to a report in the November-December issue of ... increase treatment distances to more than a centimeter, which ...
Cached Medicine News:Health News:Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award 2Health News:Novel MRI Technique Shows Secondhand Smoke Damages Lungs 2Health News:Novel MRI Technique Shows Secondhand Smoke Damages Lungs 3Health News:'CVS Caremark All Kids Can' and Scholastic Distribute Free Educational Guides in Schools to Champion Acceptance and Build Self-Esteem among Second Graders 2Health News:'CVS Caremark All Kids Can' and Scholastic Distribute Free Educational Guides in Schools to Champion Acceptance and Build Self-Esteem among Second Graders 3Health News:Penn research shows transcranial magnetic stimulation effective in treating major depression 2Health News:City-dwelling women at greater risk for breast cancer 2Health News:New method of drug delivery more effective at reaching brain tumors 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: